Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This research study is designed to investigate brain response using fMRI scan, and behavioral
responses, to treatment with the drug carbamazepine (CBZ) in patients with the painful sodium
channelopathy inherited Erythromelalgia (IEM). This study is designed to identify the central
nervous system (CNS) regions that are activated during ongoing or evoked pain attacks, and
the altered CNS response to CBZ treatment. This will advance our understanding of how IEM
affects the brain. We also hope to validate a pharmacogenic approach to the study of IEM by
use of an FDA approved drug. We hope, but cannot be sure, that subjects will directly benefit
from this study.